The $230 million AMP stakes out new target ground in Alzheimer's disease, type 2 diabetes, rheumatoid arthritis and lupus.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
PowerPoint slides
Rights and permissions
About this article
Cite this article
Mullard, A. Drug makers and NIH team up to find and validate targets. Nat Rev Drug Discov 13, 241–243 (2014). https://doi.org/10.1038/nrd4293
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4293
This article is cited by
-
Pharmacogenomics in diabetes mellitus: insights into drug action and drug discovery
Nature Reviews Endocrinology (2016)